|
|||||||||||||||||||||||||
I have recently been asked by a French company to trial a novel product in the treatment of atopic dermatitis. This product is a tyrosine kinase inhibitor. Tyrosine kinase is involved in mast cell growth and differentiation. Mast cell degranulation is an important part in the aetiopathogenesis of atopic dermatitis. This drug has also an action against mast cell tumours but the study I am involved in is purely for dogs with atopic dermatitis that fulfil certain criterion which are specified in the following atopic dermatitis attachments. I would encourage vets who think that they have dogs who fulfil this atopic dermatitis criterion to consider to refer to me for screening and , if possible, inclusion onto the scheme. Please consider if the atopic dermatitis client is dedicated enough to see this through and be aware that 33% of the dogs are put on placebo. I am more than happy to discuss the atopic dermatitis study in more detail with any vets who wish to refer a case. Please phone 0151 548 6826 or email me via the submission page or at Anthony@theskinvet.co.uk WANTED: Dogs With Atopic Dermatitis Over 1 Year of Age As part of a atopic dermatitis study evaluating an investigational drug for the treatment of pruritus in dogs with non-seasonal atopy. Requirements: Dog’s with atopic dermatitis with at least 3 of the 5 following criteria:
Criteria:
What Do Pet Owners Have To Do? Bring their dog in for examination, blood and urinary testing every two weeks and administer daily medication. What Do Pet Owners Receive? All atopic dermatitis evaluations, testing and medications will be paid for by investigators (including intradermal allergy testing) after initial screening allowing them to come into the trial This study is being conducted by Mr Anthony Chadwick BVSc CertVD MRCVS For more information on this atopic dermatitis study please contact Anthony@theskinvet.co.uk or 01515486826 Plaquette |
Shopping Basket
Note: All prices in British Pounds
|
||||||||||||||||||||||||